single infusion of Rituximab

Phase 1Monoclonal antibody

AAssistance Publique - Hôpitaux de Paris

single infusion of Rituximab is one of 10 small molecule programs targeting Venous malformation. It is currently in Phase 1.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Venous MalformationNot yet recruiting

Venous MalformationPhase 1

Not yet recruiting

Competition

Competitive Landscape

11 competitors in Venous Malformation

#DrugCompanyPhaseTrials

Depo-Provera

Pfizer

Approved

1 2

Eliquis

Bristol-Myers Squibb

Phase 2

1 3

FCN-159

SShanghai Fosun Pharmaceutical Industrial Development Co. Ltd.

Phase 2

1 4

KP-001

KKaken Pharmaceutical

Phase 3

1 5

Blenoxane

Bristol-Myers Squibb

Preclinical

2 6

Calciparine

BBaxter Healthcare Corporation

Preclinical

1 7

Precedex

MMcNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc.

Preclinical

1 8

Alcohol

Astellas

Preclinical

—9

single infusion of Rituximab

AAssistance Publique - Hôpitaux de Paris

Phase 1

1 10

Detralex

SServier Russia

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2027

Phase 2/3Recruiting

Nephrotic Syndrome

NCT05786768

Q4 2028

Phase 1Not yet recruiting

Venous Malformation

NCT07075757

Clinical

Trials by Indication[1]

Venous malformation1 trial

In Situ Injection of Anti-angiogenics in Patients With Brain Arteriovenous Malformations Not Eligible for Exclusion Treatment

Not yet recruiting·AAssistance Publique - Hôpitaux de Paris·Phase 1·NCT07075757·20 enrolled

Nephrotic Syndrome1 trial

Efficacy and Safety of Obinutuzumab Versus Rituximab in Childhood Steroid Dependant and Frequent Relapsing Nephrotic Syndrome

Recruiting·AAssistance Publique - Hôpitaux de Paris·Phase 2/3·NCT05786768·88 enrolled

Sources

References

[1]
ClinicalTrials.gov — 2 trial records for single infusion of Rituximab. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — single infusion of Rituximab compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for single infusion of Rituximab. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Assistance Publique - Hôpitaux de Paris company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Monoclonal antibody[2]
Highest Phase: Phase 1[1]
Company: AAssistance Publique - Hôpitaux de Paris

single infusion of Rituximab

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2027

Q4 2028

Trials by Indication[1]

Venous malformation1 trial

Nephrotic Syndrome1 trial

References

Drug Info

Quick Facts

Related News